Trinity Biotech plc announced on September 2, 2025, that it received written notice from the Nasdaq Stock Market LLC confirming full compliance with both the $1.00 per share minimum bid price requirement and the minimum market value of publicly held shares (MVPHS) requirement. The company had previously received a non-compliance notice on March 14, 2025, for falling below these thresholds.
On August 26, 2025, Nasdaq notified the company that its American Depositary Shares (ADSs) had maintained a closing bid price of $1.00 per share or greater for ten consecutive business days, from August 12 to August 25, 2025. Subsequently, on August 29, 2025, the company received a letter confirming that it had maintained an MVPHS of $15 million or greater for more than ten consecutive business days. Both matters are now officially closed.
This successful resolution removes a significant regulatory overhang and ensures Trinity Biotech's continued listing on the Nasdaq Global Select Market. Regaining compliance provides stability and supports the company's ongoing strategic initiatives, including the development of its continuous glucose monitoring solution and driving profitability growth in its diagnostics business.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.